Insulin-like growth factor binding protein-4 gene silencing in lung adenocarcinomas

Pathology International

Volumn 61, Issue 1, 2011, Pages 19-27

  Sato, Hanako ^a,b   Sakaeda, Masashi ^a   Ishii, Jun ^a   Kashiwagi, Korehito ^a   Shimoyamada, Hiroaki ^a   Okudela, Koji ^a   Tajiri, Michihiko ^c   Ohmori, Takahiro ^c   Ogura, Takashi ^c   Woo, Tetsukan ^a   Masuda, Munetaka ^a   Hirata, Kazuaki ^b   Kitamura, Hitoshi ^a   Yazawa, Takuya ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Kanagawa Prefectural Cardiovascular and Respiratory Center Hospital   (Japan)

Author keywords

Early growth response 1; Insulin like growth factor binding protein 4; Lung adenocarcinoma; Methylation; Promoter; Tumor differentiation

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; KI 67 ANTIGEN; SOMATOMEDIN BINDING PROTEIN 4;

ADULT; AGED; ARTICLE; BINDING SITE; CANCER CELL; CANCER SURGERY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LABELING INDEX; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; BINDING SITES; DNA METHYLATION; EARLY GROWTH RESPONSE PROTEIN 1; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4; KI-67 ANTIGEN; LUNG NEOPLASMS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC;

EID: 78650238900     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2010.02612.x     Document Type: Article

References (28)

1. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 1999; 20: 761-87.
2. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: From basic to clinical studies and clinical applications. Oncology 2002; 63: 317-32.
3. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824-54.
4. Hoeflich A, Yang Y, Huber S et-al. Expression of IGFBP-2, -3, and -4 mRNA during differentiation of Caco-2 colon epithelial cells. Am J Physiol 1996; 271: E922-31.
5. Qin C, Singh P, Safe S. Transcriptional activation of insulin-like growth factor-binding protein-4 by 17beta-estradiol in MCF-7 cells: Role of estrogen receptor-Sp1 complexes. Endocrinol 1999; 140: 2501-8.
6. Sato H, Yazawa T, Suzuki T et-al. Growth regulation via insulin-like growth factor binding protein-4 and -2 in association with mutant K-ras in lung epithelia. Am J Pathol 2006; 169: 1550-66.
7. Damon SE, Maddison L, Ware JL, Plymate SR. Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation. Endocrinol 1998; 139: 3456-64.
8. Ryan AJ, Napoletano S, Fitzpatrick PA, Currid CA, O'Sullivan NC, Harmey JH. Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumor growth in a murine model of breast cancer. Br J Cancer 2009; 101: 278-86.
9. Durai R, Yang SY, Sales KM, Seifalian AM, Goldspink G, Winslet MC. Increased apoptosis and decreased proliferation of colorectal cancer cells using insulin-like growth factor binding protein-4 gene delivered locally by gene transfer. Colorectal Dis 2007; 9: 625-31.
10. Thiel G, Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 2002; 193: 287-92.
11. Shimoyamada H, Yazawa T, Sato H et-al. Early growth response-1 induces and enhances vascular endothelial growth factor-A expression in lung cancer cells. Am J Pathol 2010; 177: 70-83.
12. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004; 22: 4632-42.
13. Dai B, Widen SG, Mifflin R, Singh P. Cloning of the functional promoter for human insulin-like growth factor binding protein-4 gene: Endogenous regulation. Endocrinol 1997; 138: 332-43.
14. Schwachtgen JL, Campbell CJ, Braddock M. Full promoter sequence of human early growth response factor-1 (Egr-1): Demonstration of a fifth functional serum response element. DNA Seq 2000; 10: 429-32.
15. Colby TV, Noguchi M, Henschke C et-al. Adenocarcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus, and Heart. Lyon: IARC Press, 2004; 35-44.
16. Woo T, Okudela K, Yazawa T et-al. Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer 2009; 65: 355-62.
17. Minuto F, Del Monte P, Barreca A et-al. Evidence for an increased somatomedin-C/insulin-like growth factor-I content in primary human lung tumors. Cancer Res 1986; 46: 985-8.
18. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signaling as a target for cancer intervention strategies. Endocr Relat Cancer 2001; 8: 161-73.
19. Svaren J, Ehrig T, Abdulkadir SA, Ehrengruber MU, Aatson MA, Milbrandt J. EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J Biol Chem 2000; 275: 38524-31.
20. Suda K, Tomizawa K, Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: An oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 2010; 29: 49-60.
21. Binkert C, Margot JB, Landwehr J, heinrich G, Schwander J. Structure of the human insulin-like growth factor binding protein-2 gene. Mol Endocrinol 1992; 6: 826-36.
22. Yazawa T, Sato H, Shimoyamada H et-al. Neuroendocrine cancer-specific upregulation mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. Am J Pathol 2009; 175: 976-87.
23. Nakanishi H, Matsumoto S, Iwakawa R et-al. Whole genome comparison of allelic imbalance between noninvasive and invasive small-sized lung adenocaracinomas. Cancer Res 2009; 69: 1615-23.
24. Matsumoto S, Iwakawa R, Kohno T et-al. Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma. Int J Cancer 2006; 118: 2498-504.
25. Sakamoto H, Shimizu J, Horio Y et-al. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol 2007; 212: 287-94.
26. Pfeifer GP, Rauch TA. DNA methylation patterns in lung carcinomas. Semin Cancer Biol 2009; 19: 181-7.
27. Rauch T, Wang Z, Zhang X et-al. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci USA 2007; 104: 5527-32.
28. Hassan KA, Chen G, Kalemkerian GP, Wicha MS, Beer DG. An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma. Clin Cancer Res 2009; 15: 6386-90.